SCHEMBL3344104

SCHEMBL3344104

Cc1nn2c(O)cc(CSc3cccc(F)c3F)nc2c1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 9/20 0.46
HPGD P15428 3/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MAPK1 P28482 2/20 0.44
MEN1 O00255 1/20 0.44
ALOX15 P16050 1/20 0.44
KMT2A Q03164 1/20 0.44
MAPT P10636 5/20 0.43
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 3/20 0.42
HTT P42858 2/20 0.42
NPC1 O15118 1/20 0.42
HCRTR1 O43613 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
RAB9A P51151 1/20 0.42
GLA P06280 1/20 0.41
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3344954 0.83 CXCR2 (0.51) CXCR2HPGDALDH1A1KDM4ELMNA
SCHEMBL3339262 0.82 CXCR2 (0.41) CXCR2MAPTALDH1A1HTTRAB9A
SCHEMBL13304011 0.82 CXCR2 (0.45) CXCR2
SCHEMBL3336608 0.80 CXCR2 (0.48) CXCR2HPGDSMN1; SMN2MAPK1MEN1
SCHEMBL3337248 0.79 CXCR2 (0.53) CXCR2KDM4ETSHRHSD17B10
SCHEMBL3365724 0.79 CXCR2 (0.54) CXCR2POLBMAPT
SCHEMBL3337830 0.79 CXCR2 (0.52) CXCR2MAPTKDM4ENPC1TP53
SCHEMBL3367422 0.79 CXCR2 (0.55) CXCR2SMN1; SMN2ALDH1A1LMNATP53
SCHEMBL3341624 0.77 CXCR2 (0.50) CXCR2TP53RAB9A
SCHEMBL3338758 0.76 CXCR2 (0.44) CXCR2ALDH1A1KDM4ETSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152205-A1 CXCR2 INHIBITORS NOVARTIS AG 2010-06-17 US claimed
EP-2094697-A1 5-SULFANYLMETHYL-PYRAZOLO [1,5-A]PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS Novartis AG (CH) 2009-09-02 EP claimed
WO-2008062026-A1 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS NOVARTIS AG (CH) 2008-05-29 WO claimed
US-20100152205-A1 CXCR2 INHIBITORS NOVARTIS AG 2010-06-17 US disclosed
EP-2094697-A1 5-SULFANYLMETHYL-PYRAZOLO [1,5-A]PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS Novartis AG (CH) 2009-09-02 EP disclosed
WO-2008062026-A1 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS NOVARTIS AG (CH) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152205-A1 CXCR2 INHIBITORS CXCR2, CXCR1, CXCR3 CXCR2 1/4885HPGD 172/4885POLB 3657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.